Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Genomic characteristics of neuroblastomas linked with outcomes

Ackermann S et al. Science. 2018 Dec 7. doi: 10.1126/science.aat6768

Key clinical point: A proposed mechanistic classification of clinical phenotypes in neuroblastoma is based on presence of telomere maintenance mechanisms, along with RAS and p53 mutations.

Major finding: The presence of telomere maintenance mechanisms was associated with a hazard ratio of 5.184 (P less than .001).

Study details: A genome sequencing of 416 pretreatment neuroblastomas, with tests for telomere maintenance mechanisms, RAS-pathway mutations, and p53-pathway mutations.

Disclosures: The study was funded by the German Cancer Aid, the German Ministry of Science and Education, the MYC-NET, the Deutsche Forschungsgemeinschaft, the Berlin Institute of Health, the European Union, and others. One coauthor reported financial relationships with Biogazelle and pxlence, and another reported consulting fees from NEO New Oncology.

Read the article here.

Citation:

Ackermann S et al. Science. 2018 Dec 7. doi: 10.1126/science.aat6768.